

## Effect of gallic acid on electrophysiological properties and ventricular arrhythmia following chemical-induced arrhythmia in rat

Ghaidafeh Akbari<sup>1</sup>, Mahin Dianat<sup>1\*</sup>, Mohammad Badavi<sup>1</sup>

<sup>1</sup> Department of Physiology, Persian Gulf Physiology Research Center, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

### ARTICLE INFO

#### Article type:

Original article

#### Article history:

Received: Jul 9, 2018

Accepted: Jul 21, 2019

#### Keywords:

Arrhythmia  
Electrophysiological -  
properties  
Gallic acid  
Ventricular  
Rat

### ABSTRACT

**Objective(s):** Ventricular arrhythmias including ventricular tachycardia (VT) and ventricular fibrillation (VF) are the most important causes of mortality rate. Gallic acid (GA) has beneficial effects on cardiovascular diseases. The aim of this study was to evaluate the effects of GA on electrophysiological parameters such as QRS complex, heart rate (HR), PR interval parameters, and ventricular arrhythmia following chemical induction in rat.

**Materials and Methods:** Seventy-two male rats were divided into 9 groups (n=8). Chronic groups pretreated by GA (10, 30, and 50 mg/kg, orally) and normal saline (N/S, 1 ml/kg, orally) for 10 days. At the start of the experiments (the first day) and on the final day of the experiments (tenth day), the electrocardiogram (lead II) was recorded. At acute group, GA (50 mg/kg), and anti-arrhythmic drugs such as propranolol, amiodarone, and verapamil injected via intravenous (IV). Then, arrhythmia induced by a CaCl<sub>2</sub> 2.5% solution (140 mg/kg, IV). Afterward, percentage of premature ventricular beats (PVB), VF, and VT were recorded at 1, and 3 min.

**Results:** These findings showed that chronic and acute doses of GA have positive inotropic and anti-dysrhythmic effects by significant reduction of PVB, VT and VF on comparison with the control group. These actions are comparable to anti-arrhythmic drugs such as quinidine, propranolol, amiodarone, and verapamil. GA has not significant effect on chronotropic and dromotropic properties.

**Conclusion:** Findings showed that GA has antiarrhythmic, and inotropic characteristics that suggested GA has effective for mild congestive heart failure, and cardiovascular disorders patients which susceptible to incidence of arrhythmias.

#### ► Please cite this article as:

Akbari Gh, Dianat M, Badavi M. Effect of gallic acid on electrophysiological properties and ventricular arrhythmia following chemical-induced arrhythmia in rat. Iran J Basic Med Sci 2020; 23:167-172. doi: 10.22038/IJBMS.2019.33296.7948

### Introduction

Cardiovascular diseases (CVDs) are the first reason of death in worldwide. CVDs were occurred in several conditions such as heart failure, coronary artery disease, and arrhythmia (1). Arrhythmia resulted from irregularly at impulse generation, impulse conduction in cardiac or combination of both (2). The most important etiologies of cardiac arrhythmias are congenital heart diseases, myocardial ischemia, cardiac valvular diseases, electrolyte imbalances, metabolic disturbances, acidosis or alkalosis, and drugs toxicity (3).

The different types of ventricular arrhythmia are including premature ventricular beat (PVB), ventricular tachycardia (VT), and ventricular fibrillation (VF). VT, and VF are the most important causes of mortality rate (4). Fibrillation is an arrhythmia which describe by irregular rhythm and VT is an arrhythmia with further than 4 PVB/minute (5).

Anti-arrhythmic drugs which administered for treatment or protection against arrhythmia, have many side effects which limits using of them (6). These drugs are divided into four major groups; based on Williams Wagon classification; such as sodium channel blockers (quinidine) (7), beta blocker drugs (propranolol) (8),

potassium channel blockers (amiodarone) (9), and calcium channel blockers (verapamil) (8).

With regard to efficacy and safety, natural materials are preferred to synthetic products (10). Because reduced costs and complications, the use of medicinal plants are preferred to chemical drugs (11). The beneficial effects of plants may be attributed to the presence of anthocyanins, flavonoids, and other phenolic compounds (12). In this regard, gallic acid (GA) with its anti-oxidant actions and potent free radical scavenging received much attention (13).

GA is a potent anti-oxidant belongs to the larger group of plant polyphenols known as gallotannins. It founded in vegetables, fruits (14), tea leaves, grapes, blackberry, and gallnuts (15). It has multiple biological effects including anti-allergic, anti-microbial, anti-cancer, anti-ulcer, anti-hyperglycemic, lipid homeostasis, and neuroprotective (16-22). It reduces cardiac troponin-T, lactate dehydrogenase, and creatine kinase in serum (23).

Many evidences reported that GA is a promising CVDs agent (24-26). Therefore, we evaluate the effect of GA pretreatment on electrophysiological parameters such as inotropic, chronotropic, dromotropic and ventricular arrhythmia are including VF, VT, and, PVB following

\*Corresponding author: Mahin Dianat. Department of Physiology, Persian Gulf Physiology Research Center, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Fax: +98-6133337370; Email: dianat@ajums.ac.ir; dianatmah@yahoo.com

chemical-induced arrhythmia in rat.

## Materials and Methods

### Animals

Seventy-two adult male Sprague Dawley Rats (200-250 g) were prepared from the animal house of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Rats were fed on a conventional diets and tap water *ad libitum*. They were maintained under standard conditions of humidity (50%), temperature (20-24 °C), and 12 hr light-dark cycle. At this duration time, gavage was done with GA solution by oral-gastric tube. Animals were deprived of food, but not water, overnight before experiments. All experiments were performed in accordance with Ethics Committee of Ahvaz Jundishapur University of Medical Sciences.

### Preparation of animals

First, animals were subjected to anesthesia with intra peritoneal (IP) injection of 50 mg/kg ketamine and 10 mg/kg xylazine. The femoral vein was cannulated for drug injection. The electrocardiogram (ECG) changes were monitored via lead II of ECG by Bio-Amp and power lab set up (ADInstruments Co., Australia). Interpretation of electrophysiological parameters was based on computer analyses of ECG.

### Animal grouping

Seventy-two rats were randomly divided into 9 groups (eight to each):

Group I: received normal saline (N/S), 1 ml/kg, 10 days, orally.

Group II: pretreated by GA, 10 mg/kg, 10 consecutive days, orally.

Group III: pretreated by GA, 30 mg/kg, 10 consecutive days, orally.

Group IV: pretreated by GA: 50 mg/kg, 10 consecutive days, orally.

Group V: pretreated by GA, 50 mg/kg, IV slowly.

Group VI: pretreated by quinidine, 5 mg/kg, IV slowly.

Group VII: pretreated by propranolol, 2 mg/kg, IV slowly.

Group VIII: pretreated by amiodarone, 10 mg/kg, IV slowly.

Group IX: pretreated by verapamil, 5 mg/kg, IV slowly.

**Table 1.** The effect of chronic doses of gallic acid on electrophysiological parameters in different groups

Groups	Electrophysiological parameters					
	HR (bpm)		QRS Complex (mv)		PR Interval (msec)	
	Before	After	Before	After	Before	After
Control (N/S, 1 ml/kg)	273±8	271±7	0.19±0.01	0.21±0.01	0.07±0.004	0.075±0.003
GA (10 mg/kg)	275±7	277.5±7	0.19±0.01	0.21±0.012	0.07±0.003	0.075±0.005
GA (30 mg/kg)	285±7	266±11	0.16±0.011	0.23±0.015*	0.073±0.004	0.085±0.005
GA (50 mg/kg)	275.6±11	273.8±8	0.16±0.012	0.24±0.015*	0.062±0.007	0.074±0.006

### The route of recording of electrophysiological parameters and CaCl<sub>2</sub>-induced arrhythmias

At this procedure, chemical-induced arrhythmia was done by CaCl<sub>2</sub> (140 mg/kg, IV). First, at all groups 15 min post-operation, heart rate (HR), QRS complex and PR interval were calculated by lead II. Then, CaCl<sub>2</sub> injected, incidence of PVB, VT, and VF were calculated at 1, and, 3 min as percentage.

### Statistical analysis


Results were shown as Mean±SEM. Comparisons among groups were represented using one-way ANOVA, FISHER exact test, or t-test. *P*<0.05 were considered significant.

## Results


As illustrated in Table 1, QRS complex was significantly decreased following chemical-induced arrhythmia. The doses of 30 and 50 mg/kg of GA were shown a significant effect on amplitude of QRS complex in comparison with control. The data demonstrated that GA has no significant effect on HR and PR interval.

### The effect of chronic and acute doses of GA on CaCl<sub>2</sub>-induced arrhythmia in comparison with the quinidine

As showed in Figure 1 (A and B) the antiarrhythmic



**Figure 1.** The effect of chronic (10, 30, 50 mg/kg) and acute (50 mg/kg) doses of GA on CaCl<sub>2</sub>-induced arrhythmia after 1 (A) and 3 (B) min in comparison with quinidine (5 mg/kg). Data in control group was considered as 100% and were compared to those of other groups. GA: Gallic acid; A: Acute; PVB: Premature ventricular beats; VF: Ventricular fibrillation; VT: Ventricular tachycardia. d=*P*<0.05, a=*P*<0.01, b=*P*<0.001 vs. control, c=difference with the quinidine




**Figure 2.** The effect of chronic (10, 30, 50 mg/kg) and acute (50 mg/kg) doses of GA on  $\text{CaCl}_2$ -induced arrhythmia, after 1 (A) and 3 (B) min in comparison with propranolol (2 mg/kg). Data in control group was considered as 100% and were compared to those of other groups. GA: Gallic Acid; A: Acute; PVB: Premature ventricular beats; VF: Ventricular fibrillation; VT: Ventricular tachycardia.  $d=P<0.05$ ,  $a=P<0.01$ ,  $b=P<0.001$  vs. control,  $c$ =difference with the propranolol

effects of 10, 30, 50 mg/kg GA (chronic doses) and acute (GA-A, 50 mg/kg) indicated that incidence of PVB, VT, and VF at 1 min significantly reduced in dose dependent manner in compared to the control group ( $P<0.05$ ). GA-A had better effect than other groups ( $P<0.001$ ). Quinidine and chronic GA at dose of 10 mg/kg had equal and less effect than other groups respectively.

#### The effect of acute and chronic doses of GA on $\text{CaCl}_2$ -induced arrhythmia in comparison with the propranolol

The results showed that GA at chronic (10, 30, 50 mg/kg) and acute (GA-A, 50 mg/kg) doses had significant reduction on incidence of PVB, VT and VF at first and 3 min compared to control group ( $P<0.05$ ), in a dose dependent manner. The GA-A had better effect than other groups ( $P<0.001$ ) at 1 min. In comparison among groups, GA (10 mg/kg) had equal effect with propranolol (Figures 2-A and B).




**Figure 3.** The effect of chronic (10, 30, 50 mg/kg) and acute (50 mg/kg) doses of GA on  $\text{CaCl}_2$ -induced arrhythmia after 1 (A) and 3 (B) min in comparison with amiodarone (10 mg/kg). Data in control group was considered as 100% and were compared to those of other groups. GA: Gallic Acid; A: Acute; PVB: Premature ventricular beats; VF: Ventricular fibrillation; VT: Ventricular tachycardia.  $d=P<0.05$ ,  $a=P<0.01$ ,  $b=P<0.001$  vs. control,  $c$ =difference with the amiodarone

#### The effect of acute and chronic doses of GA on $\text{CaCl}_2$ -induced arrhythmia in comparison with the amiodarone

The results showed that GA at chronic (10, 30, 50 mg/kg) and acute (GA-A, 50 mg/kg) doses had significant reduction on incidence of PVB, VT, and VF at 1 and 3 min compared to control ( $P<0.05$ ), in dose dependent manner. It was showed that GA-A had better effect than other groups ( $P<0.001$ ) at 1 min (Figures 3-A and B). In comparison among groups, GA (10 mg/kg) had equal effect with amiodarone.

#### The effect of acute and chronic doses of GA on $\text{CaCl}_2$ -induced arrhythmia in comparison with the verapamil

As showed in Figure 4 (A and B), the results showed that the 10, 30, 50 mg/kg of GA (chronic doses) and acute (GA-A, 50 mg/kg) had significant reduction on incidence of PVB, VT and VF at 1 and 3 min in compared to the control group (all  $P<0.05$ ), in a dose dependent manner. GA-A had better effect than other groups ( $P<0.001$ ) at 1 min. In comparison among groups GA (10 mg/kg) had equal effect with verapamil, and other groups had further effect.



**Figure 4.** The effect of chronic (10, 30, 50 mg/kg) and acute (50 mg/kg) doses of GA on  $\text{CaCl}_2$ -induced arrhythmia after 1 (A) and 3 (B) min in comparison with verapamil (2 mg/kg). Data in control group was considered as 100% and were compared to those of other groups. GA: Gallic acid; A: Acute; PVB: Premature ventricular beats; VF: Ventricular fibrillation; VT: Ventricular tachycardia.  $d=P<0.05$ ,  $a=P<0.01$ ,  $b=P<0.001$  vs. control,  $c$ =difference with the verapamil

## Discussion

This study showed that GA has anti-dysrhythmic effects on  $\text{CaCl}_2$ -induced arrhythmias by decreasing the incidence of VF, VT, and PVB in comparison with anti-arrhythmic drugs. GA also had positive inotropic action in comparison with rats in the control group.

The previous study, demonstrated that galate compounds attach to lipid membrane, and operated as anti-oxidant factor. These agents remarkably decreases levels of cardiac marker enzymes that disturbance structural, and functional of cardiac, and increase non-enzymatic activity of anti-oxidants in plasma such as glutathion, vitamins E and C (23). Based on the observations presented here, GA has protective effects on cardiac dysrhythmia by decreasing the incidence of VF, VT, PVB and increasing QRS complex amplitude as positive inotropic effect. In agreement, it has been shown that GA inhibits oxidant agents and eventually increase QRS complex voltage which lead to positive inotropic effect (27).

It has been reported that increased risk of ventricular arrhythmias can be accompany with prolongation of QT interval (28) which pretreatment with GA increased QRS voltage, and reduction of QT interval in rat model of liver cirrhosis following induction of bile duct ligation (29).

In agreement, another study showed that pretreatment with GA eliminated doxorubicin-induced alterations ECG such as prolongation of QT interval, ST segment, QRS complex, and P wave reduction (30).

GA as an anti-oxidant element can be used for cardiovascular protection against thrombosis due to inhibition of platelet-leukocyte interaction, P-selectin expression, and platelet aggregation (31). Furthermore, one study presented that GA preserves the lysosomal membrane damage in cardiac injury model induced by isoproterenol, and return the activities of lysosomal enzymes to near normal levels (27). Indeed, it is indicated that GA, and linoleic acid esters may act as a strong hypolipidemic agent against triglyceride, as well as low-density lipoprotein-cholesterol (LDL-c) (32). Polyphenol of GA that exists in *Vitis vinifera* (grape seed) has anti-oxidant effect 50 folds vitamin C and 20 folds vitamin E which decline ionized calcium intracellular (33, 34). Therefore, GA as an important lipid profile decreasing agent may be protect cardiovascular problems following hyperlipidemia (35).

Studies showed that GA through increasing the capacity of endogenous anti-oxidant system protected the rat isolated heart against Ischemia Reperfusion (IR)-induced injury (36, 37). Reperfusion-induced arrhythmias are the most common etiologies of sudden cardiac death, and can be generated in humans and experimental animals. VT, VF, and PVB are the most important arrhythmias which happens due to calcium excess during early minutes of reperfusion and overproduction of ROS (38).

These findings of our study suggest that GA similar to methyl maslinate, ursolic acid uvaol, and oleanolic acid has cardiotoxic and anti-dysrhythmic effects following  $\text{CaCl}_2$ -induced arrhythmias (39).

It has been shown that pretreatment with propranolol prevented the increase cAMP/PKA in acute phase of myocardial infarction (MI). Since, GA modulated of cAMP, and intracellular calcium, therefore, may be has common mechanism in anti-arrhythmic against chemical-induced arrhythmias (40). Propranolol has a membrane stabilizing effects because inhibition of sodium channels. This property may be explaining some effective role of propranolol in remedy of arrhythmias (27, 41). Furthermore, it has some clinical benefit actions and is used to treat cardiovascular diseases by stabilizing the inactivated of the channel (42).

Significant characteristic of amiodarone is prolong action potential due to inhibition of  $i_k$  channels and, then increase effective refractory period that decrease capability of cardiac for accelerated tachycardia (43). Amiodarone also terminated arrhythmias via inhibition of sodium and, calcium channels. The effect of amiodarone on electrophysiology properties is prolongation of PR interval (9). Therefore, we speculate that GA probably through similar mechanisms inhibits these arrhythmias.

## Conclusion

The results of this study such as increase in QRS complex voltage, and decrease in PVB, VT, and VF in GA pretreatment groups demonstrated inotropic, and anti-arrhythmic properties of GA as a protective agent in heart diseases. This effect of GA is comparable with

anti-arrhythmic drugs. Therefore, it can be suggested that GA will be effective for cardiovascular disorders persons, mild chronic heart failure, and patients in the face of multiple interventions which are susceptible to incidence of arrhythmias in the heart.

### Acknowledgment

Authors gratefully acknowledge the help and financial support of Physiology Research Center of Ahvaz Jundishapur University of Medical Sciences (grant No.PRC-113), Ahvaz, Iran.

### Conflicts of Interest

All authors declare that they have no conflicts of interest.

### References

- Kang N, Lee JH, Lee W, Ko JY, Kim EA, Kim JS, et al. Gallic acid isolated from *Spirogyra* sp. improves cardiovascular disease through a vasorelaxant and antihypertensive effect. *Environ Toxicol Pharmacol*. 2015; 39: 764-772.
- Dianat M, Radan M, Badavi M, Sarkaki A. The evaluation of inotropic properties and antidysrhythmic effect of vanillic acid and exercise on  $\text{CaCl}_2$ -induced arrhythmia in young and aged rats. *RJPBCS*. 2014;5:1545.
- Zern TL, Fernandez ML. Cardioprotective effects of dietary polyphenols. *J Nutr*. 2005;135:2291-2294.
- Balasundaram K, Mase S, Nair K, Umapathy K. A classification scheme for ventricular arrhythmias using wavelets analysis. *Med Biol Eng Comput*. 2013; 51:153-164.
- John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, et al. Ventricular arrhythmias and sudden cardiac death. *Lancet*. 2012; 380: 1520-1529.
- Khori V NM. Effect of *Artemisia absinthium* on electrophysiological properties of isolated heart of rats. *J Physiol Pharmacol*. 2007; 4:303-311.
- Marquez MF, Bonny A, Hernandez-Castillo E, De Sisti A, Gomez-Flores J, Nava S, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: A case series and literature review. *Heart Rhythm*. 2012; 9: 1995-2000.
- Katzung BG. Basic & clinical pharmacology. 11th ed. Tehran, arjmand book: arjmandpub; 2009. 300- 331.
- Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. *Vasc Health Risk Manag*. 2010; 6: 465-472.
- Topliss J, Clark A, Ernst E, Hufford C, Johnston G, Rimoldi J, et al. Natural and synthetic substances related to human health (IUPAC Technical Report). *Pure Appl Chem*. 2002; 74: 1957-1985.
- Kumar S, Saini M, Kumar V, Prakash O, Arya R, Rana M, et al. Traditional medicinal plants curing diabetes: A promise for today and tomorrow. *Asian J Tradit Med*. 2012; 7:178-188.
- Zhang H-Y, Wang L-F. Theoretical elucidation on structure-anti-oxidant activity relationships for indolinic hydroxylamines. *Bioorg Med Chem Lett*. 2002; 12: 225-227.
- Prince PSM, Priscilla H, Devika PT. Gallic acid prevents lysosomal damage in isoproterenol induced cardiotoxicity in Wistar rats. *Eur J Pharmacol*. 2009; 615:139-143.
- Kawada M, Ohno Y, Ri Y, Ikoma T, Yuugetu H, Asai T, et al. Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. *anti-Cancer Drug*. 2001;12: 847-852.
- Choubey S, Varughese LR, Kumar V, Beniwal V. Medicinal importance of gallic acid and its ester derivatives: a patent review. *Pharm Pat Anal*. 2015; 4:305-315.
- Kim S-H, Jun C-D, Suk K, Choi B-J, Lim H, Park S, et al. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. *Toxicol Sci*. 2005; 91:123-131.
- Chanwitheesuk A, Teerawutgulrag A, Kilburn JD, Rakariyatham N. Antimicrobial gallic acid from *Caesalpinia mimosoides* Lamk. *Food Chem*. 2007;100: 1044-1048.
- Wang K, Zhu X, Zhang K, Zhu L, Zhou F. Investigation of gallic acid induced anticancer effect in human breast carcinoma MCF-7 cells. *J Biochem Mol Toxicol*. 2014; 28: 387-393.
- Sen S, Asokkumar K, Umamaheswari M, Sivashanmugam A, Subhadra Devi V. Antiulcerogenic effect of gallic acid in rats and its effect on oxidant and anti-oxidant parameters in stomach tissue. *Indian J Pharm Sci*. 2013; 75:149-155.
- Huang D-W, Chang W-C, Wu JS-B, Shih R-W, Shen S-C. Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet. *Nutr Res*. 2016; 36:150-160.
- Chao J, Huo T-I, Cheng H-Y, Tsai J-C, Liao J-W, Lee M-S, et al. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. *PloS One*. 2014; 9: e96969.
- Mansouri MT, Farbood Y, Sameri MJ, Sarkaki A, Naghizadeh B, Rafeirad M. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. *Food Chem*. 2013; 138:1028-1033.
- Priscilla DH, Prince PS. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and anti-oxidants in experimentally induced myocardial infarction in Wistar rats. *Chem-Biol Interact*. 2009; 179:118-124.
- Appeldoorn CC, Bonnefoy A, Lutters BC, Daenens K, van Berkel TJ, Hoylaerts MF, et al. Gallic acid antagonizes P-selectin-mediated platelet-leukocyte interactions: Implications for the French paradox. *Circulation*. 2005; 111:106-112.
- Jin L, Lin MQ, Piao ZH, Cho JY, Kim GR, Choi SY, et al. Gallic acid attenuates hypertension, cardiac remodeling, and fibrosis in mice with NG-nitro-L-arginine methyl ester-induced hypertension via regulation of histone deacetylase 1 or histone deacetylase 2. *J Hypertens*. 2017; 35:1502-1512.
- Kee HJ, Cho S-N, Kim GR, Choi SY, Ryu Y, Kim IK, et al. Gallic acid inhibits vascular calcification through the blockade of BMP2-Smad1/5/8 signaling pathway. *Vasc Pharmacol*. 2014; 63:71-78.
- Stanely Mainzen Prince P, Priscilla H, Devika PT. Gallic acid prevents lysosomal damage in isoproterenol induced cardiotoxicity in Wistar rats. *Eur J Pharmacol*. 2009; 615:139-143.
- De Binay K, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S, et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. *J Hepatol*. 2003;39:315-319.
- Badavi M, Barzegar F, Dianat M, Mard SA. Evaluation of the Effect of gallic acid on QT interval prolongation and serum bilirubin in rat model of liver cirrhosis. *RJPBCS*. 2016; 7: 586-592.
- Kulkarni J, Swamy AV. Cardioprotective effect of gallic acid against doxorubicin-induced myocardial toxicity in albino rats. *Indian J Health Sci Biomed Res (KLEU)*. 2015; 8: 28.
- Chang SS, Lee VS, Tseng YL, Chang KC, Chen KB, Chen YL, et al. Gallic acid attenuates platelet activation and platelet-leukocyte aggregation: involving pathways of Akt and GSK3beta. *Evid Based Complement Alternat Med: eCAM*. 2012; 2012: 683872.
- Jang A, Srinivasan P, Lee N, Song H, Lee J, Lee M, et al. Comparison of hypolipidemic activity of synthetic gallic acid-linoleic acid ester with mixture of gallic acid and linoleic acid, gallic acid, and linoleic acid on high-fat diet induced obesity in

- C57BL/6 Cr Slc mice. *Chem Biol Interact.* 2008; 174: 109-117.
33. Khori V NM, Mir - Abbasi A. Ouabaine like effects of ethanolic extract of aerial parts of *Urtica dioica* L. on isolated rabbit atrioventricular node: potential role as an anti - arrhythmic. *J Med Plants* 2008; 7: 24-32.
34. Najafi M VH, Zahednezhad F, Samadzadeh M, and Babaei H. Study the effects of hydroalcoholic extract of grape seed (*Vitis vinifera*) on infarct size and cardiac arrhythmias in ischemic-reperfused isolated rat heart. *Pharm Sci.* 2011; 16: 187-194.
35. Jang A, Srinivasan P, Lee NY, Song HP, Lee JW, Lee M, et al. Comparison of hypolipidemic activity of synthetic gallic acid-linoleic acid ester with mixture of gallic acid and linoleic acid, gallic acid, and linoleic acid on high-fat diet induced obesity in C57BL/6 Cr Slc mice. *Chem Biol Interact.* 2008; 174: 109-117.
36. Badavi M, Sadeghi N, Dianat M, Samarbafzadeh A. Effects of gallic Acid and cyclosporine a on anti-oxidant capacity and cardiac markers of rat isolated heart after ischemia/reperfusion. *Iran Red Crescent Med J.* 2014; 16: e16424.
37. Dianat M, Sadeghi N, Badavi M, Panahi M, Moghadam MT. Protective effects of co-administration of gallic Acid and cyclosporine on rat myocardial morphology against ischemia/reperfusion. *Jundishapur J Nat Pharm Prod.* 2014; 9: e17186.
38. Zhao G, Gao H, Qiu J, Lu W, X W. The molecular mechanism of protective effects of grape seed Proanthocyanidin extract on reperfusion arrhythmias in rats *in vivo*. *Biol Pharm Bull.* 2010; 33: 759-762.
39. Somova L, Shode F, Mipando M. Cardiotonic and antidysrhythmic effects of oleanolic and ursolic acids, methyl maslinate and uvaol. *Phytomedicine.* 2004; 11: 121-129.
40. Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Comparative sensitivity of microvascular endothelial cells, fibroblasts and tumor cells after *in vitro* photodynamic therapy with meso-tetra-hydroxyphenyl-chlorin. *Photochem Photobiol.* 2004; 80: 236-241.
41. Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, et al. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. *Toxicol Sci.* 2006;91:123-131.
42. Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL, Jr. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. *Front Pharmacol.* 2010; 1:144.
43. Punnam SR, Goyal SK, Kotaru VP, Pachika AR, Abela GS, Thakur RK. Amiodarone - a 'broad spectrum' antiarrhythmic drug. *Cardiovasc Hematol Disord Drug Targets.* 2010; 10: 73-81.